Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2018-06-05T01:38:28Z | - |
dc.date.available | 2018-06-05T01:38:28Z | - |
dc.date.issued | 2017-03 | - |
dc.identifier.citation | NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, v. 13, No. 3, Page. 885-896 | en_US |
dc.identifier.issn | 1549-9634 | - |
dc.identifier.issn | 1549-9642 | - |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/27993720 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/71849 | - |
dc.description.abstract | The development of resistance and subsequent metastasis makes prostate cancer a leading cause of cancer-related death among men. Hence, nanoparticle-based combination chemotherapeutics could be a viable treatment strategy. Weaimed to prepare vorinostat (Vor) and bortezomib (Bor) combination-loaded zein nanoparticles (ZNP, ZNP/VB) for treating metastatic prostate cancers. Our results revealed the successful preparation of ZNP/VB with a small particle size (similar to 160 nm) and polydispersity index (similar to 0.20). Importantly, controlled and pH-dependent drug release profiles were observed. ZNP/VB exhibited high uptake in different prostate cancer cells and, thereby, exhibited higher cytotoxicity and apoptosis. Additionally, the enhanced anti-migration effect of and induction of pro-apoptotic proteins by ZNP/VB suggest its potential effectiveness in cancer treatment. ZNP/VB showed enhanced in vivo antitumor effects compared to that observed for each free drug and their combination, with minimal toxicity. Taken together, ZNP/VB could be a potential formulation for the effective treatment of metastatic prostate cancers. (C) 2016 Elsevier Inc. All rights reserved. | en_US |
dc.description.sponsorship | This research was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (No.2015R1A2A2A01004118, 2015R1A2A2A04004806), and by the Medical Research Center Program (2015R1A5A2009124) through the NRF funded by MSIP. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | ELSEVIER SCIENCE BV | en_US |
dc.subject | Zein nanoparticles | en_US |
dc.subject | Bortezomib | en_US |
dc.subject | Vorinostat | en_US |
dc.subject | Prostate cancer | en_US |
dc.subject | LIQUID-CRYSTALLINE NANOPARTICLES | en_US |
dc.subject | GRAPHENE OXIDE | en_US |
dc.subject | DRUG-DELIVERY | en_US |
dc.subject | LIPID NANOPARTICLES | en_US |
dc.subject | ANDROGEN RECEPTOR | en_US |
dc.subject | BREAST-CANCER | en_US |
dc.subject | CELLS | en_US |
dc.subject | BORTEZOMIB | en_US |
dc.subject | VORINOSTAT | en_US |
dc.subject | RELEASE | en_US |
dc.title | Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers | en_US |
dc.type | Article | en_US |
dc.relation.no | 3 | - |
dc.relation.volume | 13 | - |
dc.identifier.doi | 10.1016/j.nano.2016.12.010 | - |
dc.relation.page | 885-896 | - |
dc.relation.journal | NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE | - |
dc.contributor.googleauthor | Thapa, Raj Kumar | - |
dc.contributor.googleauthor | Hanh Thuy Nguyen | - |
dc.contributor.googleauthor | Jeong, Jee-Heon | - |
dc.contributor.googleauthor | Shin, Beom Soo | - |
dc.contributor.googleauthor | Ku, Sae Kwang | - |
dc.contributor.googleauthor | Choi, Han-Gon | - |
dc.contributor.googleauthor | Yong, Chul Soon | - |
dc.contributor.googleauthor | Kim, Jong Oh | - |
dc.relation.code | 2017012125 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | hangon | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.